Liver Disease Patients Could See Promising Results With Baby Aspirin

Patients suffering from metabolic-associated liver disease could benefit from low-dose aspirin. A new clinical trial out of Boston found that baby aspirin could reduce the amount of liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The results were recently published in the Journal of the American Medical Association. In the small study, 80 participants between 18 and 70 were given either 81-milligram aspirin or a placebo pill. They took one pill daily for six continuous months. At the end of the trial, the participants given the low-dose aspirin experienced a 6.6 percent reduction in relative liver fat versus 3.6 percent with a placebo....